OF
DAWN

Optimize Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

Optimize Financial’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,832
Closed -$116K – 360
2025
Q2 		$116K Sell
17,832
-128
-0.7% -$881 0.07% 228
2025
Q1 		$142K Buy
17,960
+2,473
+16% +$26.6K 0.1% 211
2024
Q4 		$196K Buy
+15,487
New +$215K 0.15% 216

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Optimize Financial's DAWN Position: Q3 2025 in Review

Optimize Financial sold out of Day One Biopharmaceuticals (DAWN) in Q3 2025, closing a stake of 17,832 shares — an estimated $116K sold.

Optimize Financial first reported a position in DAWN in Q4 2024 and held it in 3 quarters. The position peaked at $196K in Q4 2024. 172 funds tracked by Wall St. Rank hold DAWN as of Q3 2025.

  • Optimize Financial reported no remaining Day One Biopharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Optimize Financial sold 17,832 Day One Biopharmaceuticals shares in Q3 2025, an estimated $116K.
  • Optimize Financial first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Optimize Financial's Day One Biopharmaceuticals position peaked at $196K in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2025.

Based on Optimize Financial's 13F filing for Q3 2025, filed 5 Nov 2025.